Avid Bioservices to Present at Upcoming Investor Conferences
TUSTIN, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that its president and chief executive officer, Roger Lias, Ph.D., will deliver corporate presentations at three upcoming investor conferences.
Details of these presentations are as follows:
- 13th Annual Wells Fargo Securities Healthcare Conference
Time/Date: 10:15 a.m. ET on Wednesday, September 5, 2018
Location: The Westin Copley Place, Boston
Room: St. George CD (3rd Floor)
- H.C. Wainwright 20th Annual Global Investment Conference
Time/Date: 11:15 a.m. ET on Thursday, September 6, 2018 (webcast available)
Location: St. Regis Hotel, New York
Room: Library (2nd Floor)
- Janney Montgomery Scott 2018 Healthcare Conference
Time/Date: 9:55 a.m. ET on Tuesday, September 18, 2018 (webcast available)
Location: The Union League Club, New York
Room: Chase
To access live webcasts of the H.C. Wainwright and Janney Montgomery Scott presentations, please visit the “Upcoming Events” page within the Investors section of the Avid Bioservices website at: . Additionally, replays of the webcasts will be available on the Avid website following the conferences.
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
